HRP970699B1 - Method for the crystallisation of a tetrahydropyridin derivative and resulting crystalline forms - Google Patents
Method for the crystallisation of a tetrahydropyridin derivative and resulting crystalline formsInfo
- Publication number
- HRP970699B1 HRP970699B1 HR970699A HRP970699A HRP970699B1 HR P970699 B1 HRP970699 B1 HR P970699B1 HR 970699 A HR970699 A HR 970699A HR P970699 A HRP970699 A HR P970699A HR P970699 B1 HRP970699 B1 HR P970699B1
- Authority
- HR
- Croatia
- Prior art keywords
- crystallisation
- crystalline forms
- resulting crystalline
- naphth
- trifluoromethylphenyl
- Prior art date
Links
- 238000002425 crystallisation Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical class C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- WVHBEIJGAINUBW-UHFFFAOYSA-N Xaliproden hydrochloride Chemical compound Cl.FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=C4C=CC=CC4=CC=3)CC=2)=C1 WVHBEIJGAINUBW-UHFFFAOYSA-N 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- WJJYZXPHLSLMGE-UHFFFAOYSA-N xaliproden Chemical compound FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=C4C=CC=CC4=CC=3)CC=2)=C1 WJJYZXPHLSLMGE-UHFFFAOYSA-N 0.000 abstract 2
- 230000008025 crystallization Effects 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 238000010992 reflux Methods 0.000 abstract 1
- 238000003756 stirring Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Metoda za kristalizaciju 1-[2-(naft-2-il)etil]-4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropiridin hidroklorida (SR 57746 A), naznačena time, da: (a) SR 57746 A se grije refluksiranjem u smjesi etanola/vode 95/5 do 70/30 dok otapanje nije potpuno, (b) nastala otopina se hladi uz temperaturni gradijent od 5 do 30°C po satu i brzinu miješanja od 0 do 600 okretaja po minuti, iizolira se smjesa oblikI/oblik III 1-[2-(naft-2-il)etil]-4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropiridin hidroklorida u omjeru 80/20 do 60/40. Patent sadrži još 11 patentnih zahtjeva.Method for the crystallization of 1- [2- (naphth-2-yl) ethyl] -4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine hydrochloride (SR 57746 A), characterized in that: (a) SR 57746 A is heated by refluxing in a mixture of ethanol / water 95/5 to 70/30 until dissolution is complete, (b) the resulting solution is cooled with a temperature gradient of 5 to 30 ° C per hour and a stirring speed of 0 to 600 revolutions per minutes, a mixture of Form I / Form III 1- [2- (naphth-2-yl) ethyl] -4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine hydrochloride is isolated in a ratio of 80/20 to 60 / 40. The patent contains 11 more patent claims.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9615904A FR2757543B1 (en) | 1996-12-23 | 1996-12-23 | PROCESS FOR THE CRYSTALLIZATION OF A TETRAHYDROPYRIDINE DERIVATIVE AND CRYSTALLINE FORMS THUS OBTAINED |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP970699A2 HRP970699A2 (en) | 1998-10-31 |
HRP970699B1 true HRP970699B1 (en) | 2007-03-31 |
Family
ID=9499043
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR970699A HRP970699B1 (en) | 1996-12-23 | 1997-12-22 | Method for the crystallisation of a tetrahydropyridin derivative and resulting crystalline forms |
Country Status (39)
Country | Link |
---|---|
EP (1) | EP0950050B1 (en) |
JP (2) | JP4499188B2 (en) |
KR (1) | KR100586670B1 (en) |
CN (1) | CN1129580C (en) |
AR (1) | AR009672A1 (en) |
AT (1) | ATE307802T1 (en) |
AU (1) | AU736697B2 (en) |
BR (1) | BR9714081A (en) |
CA (1) | CA2275596C (en) |
CO (1) | CO5070688A1 (en) |
CZ (1) | CZ296689B6 (en) |
DE (1) | DE69734460T2 (en) |
DK (1) | DK0950050T3 (en) |
DZ (1) | DZ2383A1 (en) |
EE (1) | EE04188B1 (en) |
EG (1) | EG21567A (en) |
ES (1) | ES2251038T3 (en) |
FR (1) | FR2757543B1 (en) |
HK (1) | HK1024002A1 (en) |
HR (1) | HRP970699B1 (en) |
HU (1) | HU227425B1 (en) |
IL (1) | IL129938A (en) |
IN (1) | IN186976B (en) |
IS (1) | IS2357B (en) |
MY (1) | MY118015A (en) |
NO (1) | NO312364B1 (en) |
NZ (1) | NZ336130A (en) |
PL (1) | PL190494B1 (en) |
RS (1) | RS49882B (en) |
RU (1) | RU2192416C2 (en) |
SA (1) | SA98180971B1 (en) |
SI (1) | SI0950050T1 (en) |
SK (1) | SK285088B6 (en) |
TR (1) | TR199901363T2 (en) |
TW (1) | TW518322B (en) |
UA (1) | UA60324C2 (en) |
UY (1) | UY24825A1 (en) |
WO (1) | WO1998028271A1 (en) |
ZA (1) | ZA9711576B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2757543B1 (en) * | 1996-12-23 | 1999-04-02 | Sanofi Sa | PROCESS FOR THE CRYSTALLIZATION OF A TETRAHYDROPYRIDINE DERIVATIVE AND CRYSTALLINE FORMS THUS OBTAINED |
FR2782082B3 (en) * | 1998-08-05 | 2000-09-22 | Sanofi Sa | CRYSTALLINE FORMS OF (R) - (+) - N - [[3- [1-BENZOYL-3- (3,4- DICHLOROPHENYL) PIPERIDIN-3-YL] PROP-1-YL] -4-PHENYLPIPERIDIN-4 - YL] -N-METHYLACETAMIDE (OSANETANT) AND PROCESS FOR THE PREPARATION OF SAID COMPOUND |
US9272068B2 (en) | 2010-03-12 | 2016-03-01 | Nippon Shokubai Co., Ltd. | Process for producing water-absorbing resin |
KR101879468B1 (en) * | 2011-04-15 | 2018-07-17 | 엠큐어 파마슈티컬즈 리미티드 | Process for preparation of rilpivirine intermediate |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2531707A1 (en) * | 1982-08-16 | 1984-02-17 | Midy Spa | SUBSTITUTED TRIFLUOROMETHYLPHENYLTETRAHYDROPYRIDINES WITH ANOREXIGENIC ACTIVITY, A PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITIONS |
FR2757543B1 (en) * | 1996-12-23 | 1999-04-02 | Sanofi Sa | PROCESS FOR THE CRYSTALLIZATION OF A TETRAHYDROPYRIDINE DERIVATIVE AND CRYSTALLINE FORMS THUS OBTAINED |
-
1996
- 1996-12-23 FR FR9615904A patent/FR2757543B1/en not_active Expired - Fee Related
-
1997
- 1997-12-19 AR ARP970106029A patent/AR009672A1/en not_active Application Discontinuation
- 1997-12-22 HR HR970699A patent/HRP970699B1/en not_active IP Right Cessation
- 1997-12-22 MY MYPI97006233A patent/MY118015A/en unknown
- 1997-12-22 DZ DZ970233A patent/DZ2383A1/en active
- 1997-12-23 UA UA99063521A patent/UA60324C2/en unknown
- 1997-12-23 IL IL12993897A patent/IL129938A/en not_active IP Right Cessation
- 1997-12-23 EP EP97952986A patent/EP0950050B1/en not_active Expired - Lifetime
- 1997-12-23 TR TR1999/01363T patent/TR199901363T2/en unknown
- 1997-12-23 CO CO97074792A patent/CO5070688A1/en unknown
- 1997-12-23 CZ CZ0229299A patent/CZ296689B6/en not_active IP Right Cessation
- 1997-12-23 PL PL97334256A patent/PL190494B1/en not_active IP Right Cessation
- 1997-12-23 SI SI9730720T patent/SI0950050T1/en unknown
- 1997-12-23 WO PCT/FR1997/002393 patent/WO1998028271A1/en active IP Right Grant
- 1997-12-23 EG EG138397A patent/EG21567A/en active
- 1997-12-23 ES ES97952986T patent/ES2251038T3/en not_active Expired - Lifetime
- 1997-12-23 BR BR9714081-3A patent/BR9714081A/en not_active Application Discontinuation
- 1997-12-23 DE DE69734460T patent/DE69734460T2/en not_active Expired - Lifetime
- 1997-12-23 RU RU99116597/04A patent/RU2192416C2/en not_active IP Right Cessation
- 1997-12-23 CN CN97180863A patent/CN1129580C/en not_active Expired - Fee Related
- 1997-12-23 AU AU56684/98A patent/AU736697B2/en not_active Ceased
- 1997-12-23 IN IN3761DE1997 patent/IN186976B/en unknown
- 1997-12-23 UY UY24825A patent/UY24825A1/en not_active IP Right Cessation
- 1997-12-23 DK DK97952986T patent/DK0950050T3/en active
- 1997-12-23 CA CA002275596A patent/CA2275596C/en not_active Expired - Fee Related
- 1997-12-23 SK SK828-99A patent/SK285088B6/en not_active IP Right Cessation
- 1997-12-23 HU HU0001387A patent/HU227425B1/en not_active IP Right Cessation
- 1997-12-23 EE EEP199900264A patent/EE04188B1/en not_active IP Right Cessation
- 1997-12-23 RS YUP-289/99A patent/RS49882B/en unknown
- 1997-12-23 NZ NZ336130A patent/NZ336130A/en not_active IP Right Cessation
- 1997-12-23 JP JP52848198A patent/JP4499188B2/en not_active Expired - Fee Related
- 1997-12-23 AT AT97952986T patent/ATE307802T1/en active
- 1997-12-23 KR KR1019997005373A patent/KR100586670B1/en not_active IP Right Cessation
- 1997-12-23 ZA ZA9711576A patent/ZA9711576B/en unknown
-
1998
- 1998-01-21 TW TW086119629A patent/TW518322B/en not_active IP Right Cessation
- 1998-03-11 SA SA98180971A patent/SA98180971B1/en unknown
-
1999
- 1999-06-10 IS IS5076A patent/IS2357B/en unknown
- 1999-06-22 NO NO19993076A patent/NO312364B1/en not_active IP Right Cessation
-
2000
- 2000-06-01 HK HK00103287A patent/HK1024002A1/en not_active IP Right Cessation
-
2009
- 2009-05-07 JP JP2009112971A patent/JP2009197022A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE240314T1 (en) | CRYSTALS OF BENZIMIDAZOLE DERIVATIVES AND METHOD FOR THEIR PRODUCTION | |
NO973635L (en) | Method of inhibiting cell-cell adhesion | |
DE69330963T2 (en) | PRODUCTION OF ALUMINOSILICATE ZOLITHES | |
NZ199990A (en) | 1,4-dihydropyridine derivatives and pharmaceutical compositions | |
NO20022558L (en) | 4-Carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as CETP inhibitor | |
JPS57171968A (en) | 1,4-dihydropyridine derivative | |
DE69218330T2 (en) | Process for the preparation of 1,4-dihydropyridines substituted at the 4-position | |
ES2093399T3 (en) | NEW DERIVATIVES OF PHOSPHONE-SUCCINIC ACID, PROCEDURE FOR ITS PREPARATION AND MEDICINES CONTAINING THESE COMPOUNDS. | |
DE69615341D1 (en) | METHOD FOR PRODUCING PARAXYLOL AT LEAST ONE CRYSTALIZATION LEVEL AT HIGH TEMPERATURE AND ONE LEVEL FOR PARTIAL MELTING OF THE CRYSTALS | |
DE69311837T2 (en) | Steroids for the treatment of prostatic hypertrophy, their production and use | |
NO174624C (en) | Cyclopropylmalonanilate derivative for inhibition of plant growth, plant growth inhibiting preparation and use thereof | |
HRP970699B1 (en) | Method for the crystallisation of a tetrahydropyridin derivative and resulting crystalline forms | |
ATE518835T1 (en) | CRYSTAL FORM OF A QUINOLINE COMPOUND AND METHOD FOR THE PRODUCTION THEREOF | |
AT379590B (en) | METHOD FOR PRODUCING NEW 4- (3-TRIFLUORMETHYLPHENYL) -1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES | |
JPS6471816A (en) | Pharmacologically useful polymetamorphosis of buspirone | |
NO922521L (en) | PIPERIDINYLETANODE DERIVATIVES WITH THERAPEUTIC EFFECT | |
DE3867281D1 (en) | CALCIUM-4,6-DIOXO-4H-PYRANO (3,2-G) -QUINOLINE-2,8-DICARBOXYLATE DERIVATIVE, METHOD FOR THE PRODUCTION THEREOF AND COMPOSITIONS CONTAINING IT. | |
DK535284A (en) | PHENYLALKANIC ACID DERIVATIVES AND PROCEDURES FOR PREPARING THEREOF | |
YU46961B (en) | PROCEDURE FOR CONVERSION OF POLYMORPH CRYSTAL FORM OF BUSPIRON CHLORHYDRATE | |
NO955242L (en) | Piperidine derivatives, processes for their preparation and their therapeutic use | |
PH21322A (en) | Anti-imflammatory polymorphic monoethanolamine salt of n-(2-pyridyl)-2-methyl-4-hydroxy-2h-1,2-benzothiazine-3-carboxamide 1,1-dioxide compound; composition and method of use therefor | |
EE9700292A (en) | Substituted phenylamidines, drugs containing these compounds and a process for their preparation | |
DE3873824T2 (en) | METHOD FOR PRODUCING ALPHA- (ALKYLPHENYL) -4- (HYDROXYDIPHENYLMETHYL) -1-PIPERIDINBUTANOL. | |
NO973103L (en) | Method for inhibiting growth hormone effects | |
DE3674117D1 (en) | METHOD FOR PRODUCING 1,4-DIHYDROPYRIDINE DERIVATIVES OVER NEW INTERMEDIATE PRODUCTS. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
PPPP | Transfer of rights |
Owner name: SANOFI-SYNTHELABO, FR |
|
PNAN | Change of the applicant name, address/residence |
Owner name: SANOFI-AVENTIS, FR |
|
B1PR | Patent granted | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20111217 Year of fee payment: 15 |
|
PBON | Lapse due to non-payment of renewal fee |
Effective date: 20121223 |